Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies.

Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S.

Expert Opin Drug Saf. 2012 May;11 Suppl 1:S9-19. doi: 10.1517/14740338.2011.606213. Epub 2011 Aug 16. Review.

PMID:
21843103
2.

[Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].

Fujii H, Iihara H, Ishihara M, Matsuhashi N, Takahashi T, Yoshida K, Itoh Y.

Gan To Kagaku Ryoho. 2016 Feb;43(2):229-33. Japanese.

PMID:
27067688
3.

Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.

Funakoshi T, Suzuki M, Tamura K.

Cancer Treat Rev. 2014 Dec;40(10):1221-9. doi: 10.1016/j.ctrv.2014.09.002. Epub 2014 Sep 19.

PMID:
25288497
4.

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

Jean GW, Shah SR.

Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. Review.

PMID:
18503402
5.

Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab).

Miroddi M, Sterrantino C, Simmonds M, Caridi L, Calapai G, Phillips RS, Stewart LA.

Int J Cancer. 2016 Nov 15;139(10):2370-80. doi: 10.1002/ijc.30280. Epub 2016 Jul 28. Review.

PMID:
27450994
6.

Cetuximab therapy and symptomatic hypomagnesemia.

Schrag D, Chung KY, Flombaum C, Saltz L.

J Natl Cancer Inst. 2005 Aug 17;97(16):1221-4. Review.

PMID:
16106027
7.

Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.

Fujii H, Iihara H, Suzuki A, Kobayashi R, Matsuhashi N, Takahashi T, Yoshida K, Itoh Y.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1209-15. doi: 10.1007/s00280-016-3039-1. Epub 2016 Apr 22.

PMID:
27106835
8.

Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.

Wang Q, Qi Y, Zhang D, Gong C, Yao A, Xiao Y, Yang J, Zhou F, Zhou Y.

Tumour Biol. 2015 May;36(5):3471-82. doi: 10.1007/s13277-014-2983-9. Epub 2014 Dec 28.

9.

[Anti-epidermal growth factor receptor monoclonal antibodies induced adverse events].

Tsuji Y, Kogawa T, Abe M.

Gan To Kagaku Ryoho. 2010 May;37(5):787-90. Japanese.

PMID:
20495307
10.

Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.

Petrelli F, Cabiddu M, Borgonovo K, Barni S.

Ann Oncol. 2012 Jul;23(7):1672-9. doi: 10.1093/annonc/mdr592. Epub 2012 Jan 11. Review.

PMID:
22241897
11.

Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer.

Cao Y, Liao C, Tan A, Liu L, Gao F.

Chemotherapy. 2010;56(6):459-65. doi: 10.1159/000321011. Epub 2010 Nov 18.

PMID:
21088398
12.

Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials.

Li X, Shan BE, Wang J, Xing LP, Guo XJ, Zhang YH, Shi PH, Wang ZY.

PLoS One. 2013 Nov 28;8(11):e81897. doi: 10.1371/journal.pone.0081897. eCollection 2013.

13.

Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy.

do Pazo-Oubiña F, Estefanell-Tejero A, Riu-Viladoms G, Anglada-Martínez H, Molas-Ferrer G, Creus-Baró N.

J Clin Pharm Ther. 2013 Apr;38(2):101-3. doi: 10.1111/jcpt.12028. Epub 2012 Dec 19.

PMID:
23278401
14.

Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.

You B, Chen EX.

J Clin Pharmacol. 2012 Feb;52(2):128-55. doi: 10.1177/0091270010395940. Review.

PMID:
21427284
15.

Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia.

Fakih M.

Oncology (Williston Park). 2008 Jan;22(1):74-6. Review. No abstract available.

16.

Re: Cetuximab therapy and symptomatic hypomagnesemia.

Altundag K, Altundag O, Baptista MZ, Turen S, Atik MA.

J Natl Cancer Inst. 2005 Dec 7;97(23):1791-2. No abstract available.

PMID:
16333039
17.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S.

Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9. Review.

PMID:
25673558
18.

Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer.

Nie F, Shen J, Tong JL, Xu XT, Zhu MM, Ran ZH.

J Dig Dis. 2009 Nov;10(4):247-57. doi: 10.1111/j.1751-2980.2009.00393.x.

PMID:
19906103
19.

Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.

Saif MW, Kaley K, Chu E, Copur MS.

Clin Colorectal Cancer. 2010 Dec;9(5):315-8. doi: 10.3816/CCC.2010.n.046.

PMID:
21208847
20.

Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.

Saif MW, Peccerillo J, Potter V.

Cancer Chemother Pharmacol. 2009 May;63(6):1017-22. doi: 10.1007/s00280-008-0831-6. Epub 2008 Sep 10.

PMID:
18781300

Supplemental Content

Support Center